Treatment With Montelukast Is Not Linked To Reduced Symptom Duration, Shorter Time To Sustained Recovery In Adult Outpatients With Mild To Moderate COVID-19 Infection, Study Finds

Infectious Disease Advisor (11/26, Chan) reports, “Treatment with montelukast is not associated with reduced symptom duration or shorter time to sustained recovery in adult outpatients with mild to moderate COVID-19 infection, according to study findings.” Investigators came to this conclusion after conducting “a double-blinded, placebo-controlled randomized clinical trial...to compare the effectiveness of montelukast with placebo on time to sustained recovery from COVID-19 infection.” The research was published in JAMA Network Open.